CD Pharma India Pvt Ltd, a wholly owned subsidiary of VSL Pharmaceuticals, has all set to launch a range of its probiotic products named as VSL#3, Oxadrop and Florisa this year in some tie-ups with major Indian pharma companies.

In an interaction with Pharmabiz, Kanwaldeep Chadha, country manager of CD Pharma & Director Asia Pacific said that within a months of time, company would introduce its research based probiotic product VSL#3. The product has completed phase III clinical trial recently in India on "Rotavirus induced Siarrhea" and is ready to be introduced in Indian market.

Talking about the efficacy of the product he said that "The efficacy of the VSL#3 has already been proven in treating disorders like IBD, IBS, and multiple organ failure, metabolic diseases and diarrhoeal diseases, including rotavirus. And, human trials are in progress across the world to test its efficacy in disorders like obesity related fatty liver disease, asthma and food related allergy" he added.

He informed that VSL#3 would also be launched under exclusive in-licensing agreement with a leading company.

Besides, the company is also having some other products in pipeline to be in-licensed. Among them, 'Florisa' (specific mixture of strain for gynaecological disorder/ STD) to treat bacterial Vaginosis and prevent HSV and possibly HIV and HPV will be introduced by November this year.

Another product 'Oxadrop' a lactic acid bacteria at high concentration specifically degrading enteral oxalate, to treat hyperoxalate associated with short gut syndrome and bariatric surgery would also be in the list of the in-licensing this year, he added.

Informing about the recent in-licensing agreement with Ranbaxy to market its 'Inersan' brand in India and Nepal, he said that the international clinical trials of this product had shown that the drug had remarkable result in treating the dental problems such as Periodontitis, Gingivitis and Halitosis. "In India we have had some encouraging results in this regard. We are also planning to introduce more research based probiotic products in the near future" he added.